22 Advanced Solid Tumors Clinical Trials in Portland, IN (2026)

Q: How do I join a clinical trial in Portland?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Portland research site will contact you.

Recruiting Advanced Solid Tumors Studies in Portland

NCT03739827Recruiting

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

Background: Approximately 150 cases of cancer per one million per year are considered rare cancers. While all tumors originate from genetic changes, a small percentage of these tumors are familial. R...

Portland, IN10,000 participantsNational Cancer Institute (NCI)

View Study Details

NCT05417594Recruiting

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participan...

Portland, IN695 participantsAstraZeneca

View Study Details

NCT05875168Recruiting

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors....

Portland, IN540 participantsDaiichi Sankyo

View Study Details

NCT05669430Recruiting

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care....

Portland, IN365 participantsGV20 Therapeutics

View Study Details

NCT06130553Recruiting

A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors

This is a first time in human (FTiH) Phase I/IIa, open-label, multi-centre study of AZD3470 in participants with advanced or metastatic solid tumors with MTAP deficiency. The study consists of several...

Portland, IN334 participantsAstraZeneca

View Study Details

NCT05753722Recruiting

A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors....

Portland, IN270 participantsIncendia Therapeutics

View Study Details

NCT05768932Recruiting

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

This study is a multiple cohort, multicenter, open-label Phase 1 study with dose-escalation substudies investigating intravenous (IV) BAL0891 as monotherapy, and in combination with tislelizumab or pa...

Portland, IN260 participantsSillaJen, Inc.

View Study Details

NCT06459973Recruiting

A Clinical Study of YL205 in Patients With Advanced Solid Tumors

This study is a multicenter, open-label, phase I/II study of YL205 in China to evaluate the safety, tolerability, PK characteristics and preliminary efficacy of YL205 in the following selected patient...

Portland, IN252 participantsMediLink Therapeutics (Suzhou) Co., Ltd.

View Study Details

NCT06242470Recruiting

A Study of MGC026 in Participants With Advanced Solid Tumors

The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, ...

Portland, IN250 participantsMacroGenics

View Study Details

NCT07205718Recruiting

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

TAK-188 is a new medicine that targets a protein called CCR8, which is found on the surface of certain cells (Tregs) inside tumors. These cells can weaken the body's ability to fight cancer. TAK-188 m...

Portland, IN223 participantsTakeda

View Study Details

NCT06577987Recruiting

Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors....

Portland, IN220 participantsCircle Pharma

View Study Details

NCT05981703Recruiting

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced so...

Portland, IN217 participantsBeOne Medicines

View Study Details

NCT05422911Recruiting

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

The investigators have used national VHA data to demonstrate real-world efficacy of abiraterone and enzalutamide in Veterans with mCRPC. In the real-world that is the VHA, the investigators have succe...

Portland, IN192 participantsSun Pharmaceutical Industries Limited

View Study Details

NCT06251310Recruiting

SW-682 in Advanced Solid Tumors

This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with...

Portland, IN186 participantsSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

View Study Details

NCT05873686Recruiting

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected...

Portland, IN140 participantsNuvectis Pharma, Inc.

View Study Details

NCT06974110Recruiting

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clini...

Portland, IN132 participantsMOMA Therapeutics

View Study Details

NCT06719362Recruiting

A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies

Phase 1 first-in-human, open-label, dose-escalation (3 + 3), dose-expansion clinical trial to evaluate the safety, tolerability and preliminary clinical efficacy of M3T01 (fully human IgG4/kappa monoc...

Portland, IN110 participantsProvidence Health & Services

View Study Details

NCT06171750Recruiting

Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

This is a Phase 1, multicenter, open-label dose escalation study to determine the safety and tolerability of intratumoral (IT) injection of tolododekin alfa (ANK-101) in participants with advanced sol...

Portland, IN97 participantsAnkyra Therapeutics, Inc

View Study Details

NCT06234098Recruiting

Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

This is a first-in-human, multicenter, open-label, dose escalation and dose expansion Phase 1/2 study to determine the MTD and/or the recommended Phase 2 dose (RP2D) and to characterize DLTs of AT-196...

Portland, IN85 participantsAlyssum Therapeutics

View Study Details

NCT06809114Recruiting

FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors

A Phase I, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AT03-65 in Adults with Advanced Solid Tumors...

Portland, IN83 participantsAxcynsis Therapeutics Pte Ltd

View Study Details

NCT06402201Recruiting

First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors

CDR404 is a highly potent and specific T-cell engaging bispecific and bivalent antibody designed for the treatment of cancers positive for the tumor-associated antigen melanoma-associated antigen 4 (M...

Portland, IN42 participantsCDR-Life AG

View Study Details

NCT07356453Recruiting

A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.

The goal of this interventional study is to evaluate the safety and tolerability of escalating doses of FORX-48 as monotherapy in patients with select advanced solid tumors with BRCA1/2 mutations or o...

Portland, IN40 participantsFoRx Therapeutics AG

View Study Details

About Advanced Solid Tumors Clinical Trials in Portland

Advanced solid tumors refer to cancers that have grown beyond the original site or spread to distant organs. Many clinical trials enroll patients with various types of advanced solid tumors to test novel therapies. These trials often investigate immunotherapy, targeted therapy, and combination approaches.

There are currently 22 advanced solid tumors clinical trials recruiting participants in Portland, IN. These studies are seeking a combined 14,733 participants. Research is being sponsored by National Cancer Institute (NCI), AstraZeneca, Daiichi Sankyo and 18 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Advanced Solid Tumors Clinical Trials in Portland — FAQ

Are there advanced solid tumors clinical trials in Portland?

Yes, there are 22 advanced solid tumors clinical trials currently recruiting in Portland, IN. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Portland?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Portland research site will contact you about next steps.

Are clinical trials in Portland free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Portland studies also compensate for your time and travel.

What advanced solid tumors treatments are being tested?

The 22 active trials in Portland are testing new therapies including novel drugs, biologics, and treatment approaches for advanced solid tumors.

Data updated July 13, 2026 from ClinicalTrials.gov